Guardant Health Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook

About this update from Guardant Health, Inc.

[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1806,"height":619,"url":"https://media.zenfs.com/en/business-wire.com/bf58dd910efdd878254b9181af1f889b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/4E28zVhGnfQDdey6j.TOmA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMyOTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/bf58dd910efdd878254b9181af1f889b","width":960,"height":329},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/WFsCWr1ECwmvKTqAHR6HfA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD04MjI7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/bf58dd910efdd878254b9181af1f889b","width":1200,"height":411}},"lazy":false},{"type":"text","content":"Fourth quarter 2025 revenue growth of 39% broadly driven by strong performance across Oncology and Screening","length":108,"tagName":"p","attribs":{}},{"type":"text","content":"Expects full year 2026 total revenue to grow in the range of 27% to 30% year-over-year","length":86,"tagName":"p","attribs":{}},{"type":"text","content":"PALO ALTO, Calif., February 19, 2026--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter and full year ended December 31, 2025.","length":216,"tagName":"p"},{"type":"text","content":"Fourth Quarter 2025 Financial Highlights","length":40,"tagName":"p"},{"type":"text","content":"For the three-month period ended December 31, 2025, as compared to the same period of 2024:","length":91,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Reported total revenue of $281.3 million, an increase of 39%, driven by:","length":72,"tagName":"p","attribs":{}},{"type":"list","items":[{"val":[{"type":"text","content":"Oncology revenue of $189.9 million, an increase of 30%, and approximately 79,000 oncology tests, an increase of 38%","length":115,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Biopharma & Data revenue of $54.0 million, an increase of 9%","length":64,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Screening revenue of $35.1 million, and approximately 38,000 Shield screening tests, compared to 6,400 tests in the prior year period","length":133,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":312,"olType":false}...

More updates from Guardant Health, Inc.